Hiroko Ueda1, Jun Goto, Hideji Hashida
1Department of Molecular Therapeutics, Tokyo Metropolitan, Institute for Neuroscience, 2-6, Musashi-dai, Fuchu, Tokyo 183-8526, Japan.
Small ubiquitin-like modifiers (SUMOs) activate in polyglutamine diseases, including DRPLA, SCA1, MJD, and Huntington's disease. This SUMO-1 system activation suggests its involvement in the neurological pathology of these conditions.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: